List view / Grid view

News

Pfizer expands its R&D investment strategy

12 January 2016 | By Victoria White

The first four investments of the newly focused initiative include $46 million in financing to companies at early stages of the discovery process that are actively exploring Conditionally Active Biologics (CABs), immuno-oncology, neurodegenerative technologies and gene therapy...

MSD acquires drug discovery company IOmet

12 January 2016 | By Victoria White

The acquisition includes IOmet's comprehensive preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors...